Robin L. Jones, BSc, MB, MRCP, MD (Res)
Director, Bob and Eileen Gilman Family Sarcoma Research Program
Clinical Research Division
Fred Hutchinson Cancer Research Center
Division of Medical Oncology
University of Washington
Seattle Cancer Care Alliance
825 Eastlake Ave E, G3630
Seattle, WA 98109-1023
- Yaddi Ty
- Fax: 206.88.6618
Specialty / Expertise
- Bone and soft tissue sarcoma
Phase I trials
- The Sarcoma Unit at the Seattle Cancer Care Alliance provides an experienced multi disciplinary team to manage bone and soft tissue sarcomas. It is important for patients with rare diseases to be provided with detailed up to date information. This is a crucial component of their care. I also believe the role of the medical oncologist is to develop new therapies with emphasis on the biological characteristics of each sarcoma subtype.
Identification of biomarkers predictive of therapeutic effect
Current Research Projects
Development of novel therapeutic strategies for the treatment of sarcomas through clinical trials
- Dr. Jones received his BSc in Radiology and Medical Physics with First Class honors from Guy's and St. Thomas' Hospitals, University of London in 1993 and in 1996, continued on to receive his MB BS in Medicine. In 2001, he received his MRCP from the Royal College of Physicians in London and acquired his MD (Res) at the Institute of Cancer Research with the University of London in 2006 in addition to receiving Medical Oncology Training at Royal Marsden Hospital.
Schoffski P, Taron M, Jimeno J, Grosso F, Sanfilipo R, Casali P, Le Cesne A, Jones RL, Blay, J-Y, Poveda A, Maki, R, Nieto A, Tercero JC, Rosell R. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin. Epublished European Journal of Cancer March 2011.
Pollack S, Loggers ET, Rodler ET, Yee C, Jones RL. Immune based therapies for Sarcoma. Epublished by Sarcoma January 2011.
Ganeshalingam S, Rajeswaran G, Jones RL, Thway K, Moskovic E. Leiomyosarcomas of the inferior vena cava: diagnostic features on cross-sectional imaging . Clinical Radiology 66; 50-56: January 2011.
Jones RL, Rojo FG, A’Hern R, Villena N, Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho J, Dowsett M, Albanell J. Nuclear NF-kB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. Journal of Clinical Pathology epublished December 2010.
Jones RL, Olmos D, Thway K, Fisher C, Tunariu N, Postel-Vinay S, Scurr M, de Bono J, Kaye SB, Judson IR. Clinical benefit of Phase I participation for advanced sarcoma patients. Cancer Chemotherapy Pharmacology epublished November 2010.
Jones RL, Constantinidou A, Olmos D, Thway K, Fisher C, Al-Muderis O, Scurr M, Judson IR. The role of palliative chemotherapy in advanced epithelioid sarcoma. Epublished American Journal of Clinical Oncology October 2010.
Dedes KJ, Natrajan R, Lambros MB, Geyer FC, Lopez-Garcia MA, Savage K, Jones RL, Reis-Filho JS. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. European Journal of Cancer epublished September 2010.
Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well tolerated treatment for refractory aggressive fibromatosis. European Journal of Cancer 45(17); 2930-2934: 2009.
Jones RL, McCall J, Adam A, O’Donnell D, Ashley S, Al-Muderis O, Thway K, Fisher C, Judson IR. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. European Journal of Surgical Oncology 36(5); 477-482: 2010.
Jones RL, Salter J, A’Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment 119(2); 315-323: 2010.
Jones RL, Walsh G, Ashley S, Chua S, Agarwal R, O'Brien M, Johnston S, Smith IE. A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. British Journal of Cancer 100(2); 305-310: 2009.
Jones RL, Salter J, A’Hern R, Nerurkar A, Parton M, Reis-Filho JS, Smith IE, Dowsett M. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Research and Treatment 11(6); 53-68: 2008.
Tan DSP, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Ashworth A, Reis-Filho JS. Triple Negative Breast Cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Research and Treatment 111(1); 27-44: 2008.
Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncology 8(7); 595-602: 2007.
Last updated: May 2011